Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study

Nienke Legdeur 1*, Maryam Badissi 1, Stephen F. Carter 2, Sophie de Crom 1, Aleid van de Kreeke 3, Ralph Vreeswijk 4, Marijke C. Trappenburg 5, Mardien L. Oudega 6, Huiberdina L. Koek 7, Jos P. van Campen 8, Carolina J. P. W. Keijsers 9, Chinenye Amadi 2, Rainer Hinz 2, Mark F. Gordon 10, Gerald Novak 11, Jana Podhora 12, Erik Serné 13, Frank Verbraak 3, Maqsood Yaqub 14, Arjan Hillebrand 15, Alessandra Griffa 16, Neil Pendleton 2, Sophia E. Kramer 17, Charlotte E. Teunissen 18, Adriaan Lammertma 14, Frederik Barkhof 14,19, Bart N. M. van Berckel 14, Philip Scheltens 1, Majon Muller 13, Andrea B. Maier 20,21, Karl Herholz 2 and Pieter Jelle Visser 1,22

Abstract

Background: The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience in the oldest-old and described the design of the EMIF-AD 90+ Study.

Methods: The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer’s Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid ß and tau in cerebrospinal fluid/blood and neurophysiological measures.

Discussion: The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration.

Trial registration: Nederlands Trial Register NTR5867. Registered 20 May 2016.

Keywords: Alzheimer’s disease, Dementia, Cognitive impairment, Amnestic mild cognitive impairment, Resilience, Oldest-old, Amyloid, Positron emission tomography, Magnetoencephalography (MEG)
**Background**

**Introduction**

The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society [1]. Worldwide, the number of oldest-old subjects is expected to increase to 71.2 million in 2050, a 5-fold increase of the current oldest-old population [2, 3]. The oldest-old have a high risk of developing dementia with a prevalence up to 40% [4]. The increasing number of oldest-old subjects with dementia will have major clinical and financial consequences for patients, their families and society as a whole [5].

Still a considerable number of subjects remain cognitively normal at high age, indicating the presence of protective factors for cognitive impairment in these subjects. Identification of these protective factors is crucial and will have implications for preventive strategies. In addition, identifying the neurodegenerative markers associated with cognitive impairment in the oldest-old, will enhance our understanding of the underlying pathophysiology in this specific age group.

The EMIF-AD 90+ study was set-up to investigate protective factors for cognitive impairment in the oldest-old. We will first provide an overview of the current status of research on this topic and then present the study outline of the EMIF-AD 90+ study.

**Review on studies on cognitive impairment in the oldest-old**

We searched for studies focusing on protective factors for cognitive impairment in nonagenarians, which gave us two results: The 90+ Study in the USA and the Danish Birth Cohort Studies [6, 7]. Broadening the search to studies that started inclusion from the age of 85 years or focused on successful aging resulted in eight more studies: the H85 Gothenburg study, Leiden 85-plus Study, Newcastle 85+ Study, NonaSantfeliu study, Octabaix study, Project of Longevity and Aging in Dujangyan (PLAD), Umeå study and Vantaa 85+ Study [8–15]. Table 1 shows the design characteristics of these ten studies.

**Protective factors for cognitive impairment in the oldest-old**

Table 2 summarizes the findings on the protective factors for cognitive impairment or dementia of the ten studies. A high level of education was found to be protective against dementia in the oldest-old and one study indicated that high cognitive activity, examined by looking at the time spend on reading, around age 90 years was related to resilience to dementia [4, 16–18]. The influence of vascular comorbidities on cognition has been studied quite extensively in this age group. Most studies did not find an association between cholesterol levels and cognition in the oldest-old [15, 17, 19–22]. Hypertension has mostly been found to be protective in the oldest-old, especially when hypertension is diagnosed after the age of 80 years [17, 19, 23–27]. This is in contrast to studies that have shown a higher dementia risk in the presence of midlife hypertension [28]. In addition, although midlife diabetes mellitus has been related to dementia in younger subjects [29], the influence of diabetes mellitus on cognition might be less evident in the oldest-old [11, 30, 31]. The protective effect related to the absence of stroke seemed to persist in the oldest-old [18, 32] and one study on atrial fibrillation and dementia did not find an association [32]. The absence of depressive symptoms seemed to be associated with resilience to cognitive impairment, which is consistent with findings in younger subjects [14, 33, 34]. One study related sleep quality to cognition and reported a higher sleep quality in subjects without cognitive impairment, which is in line with results in younger subjects [35, 36]. With regard to the sensory system, visual and auditory impairments have been associated with worse cognitive functioning in the oldest-old [37, 38] and although olfactory impairment has been associated with incident dementia in a younger age group [39], no studies were found studying this in the oldest-old.

Data about physical performance and activity have been collected in the Leiden 85-plus study and The 90+ Study. Good physical performance, measured with handgrip strength, 4 m walk or standing balance tests, was associated with better cognitive functioning and lower dementia incidence in the oldest-old but high physical activity did not seem to influence dementia incidence [16, 40, 41].

With regard to genetics, the Apolipoprotein E (APOE) genotype, a major risk factor for AD in younger subjects, has been extensively studied in the oldest-old, with mixed results regarding the relation to cognition and dementia [42–46]. The Danish 1905 birth cohort, PLAD and Vantaa 85+ Study also studied a number of other genotypes in the oldest-old and found some additional protective and risk genotypes which are described in Table 2.

**Hallmarks of aging and cognition in the oldest-old**

Hallmarks of aging [47], such as inflammation and cellular senescence [48], have been scarcely studied in relation to cognition in the oldest-old. The Leiden 85-plus Study and The 90+ Study related inflammation markers to cognition and dementia but showed mixed results [49–51]. In addition, telomere length measured in white blood cells were not associated with cognition, dementia prevalence or incident dementia [52].

**Markers of neurodegeneration and cognition in the oldest-old**

Limited information is available about the relation of markers of neurodegeneration, such as amyloid β and tau measured in cerebrospinal fluid (CSF) and/or with a positron emission tomography (PET) scan with cognitive impairment in the oldest-old. Postmortem studies have
| Domain                      | Danish Birth Cohort Studies [6] | H85 Gothen-burg study [12] | Leiden 85-plus Study [8] | Newcastle 85+ Study [10] | NonaSant-feliu study [8] | Octabaix study [13] | PLAD [15] | The 90+ Study, USA [7] | Umeå 85+ study [14] | Vantaa 85+ Study [11] |
|-----------------------------|---------------------------------|----------------------------|--------------------------|--------------------------|----------------------------|----------------------|-----------|------------------------|----------------------|----------------------|
| Cognitive reserve           | +                               | +                          | +                        | +                        | +                          | +                    | +         | +                      | +                    | +                    |
| Vascular comorbidity        | +                               | +                          | +                        | +                        | +                          | +                    | +         | +                      | +                    | +                    |
| Mood and sleep              | +                               | +                          | +                        | +                        | +                          | +                    | +         | +                      | +                    | +                    |
| Sensory system              | –                               | –                          | +                        | +                        | +                          | +                    | –         | –                      | +                    | +                    |
| Physical performance and capacity | +                             | –                          | +                        | +                        | +                          | +                    | +         | +                      | +                    | +                    |
| Genetics                    | +                               | +                          | +                        | +                        | +                          | –                    | +         | –                      | +                    | +                    |
| Hallmarks of aging\(b\)    | –                               | –                          | +                        | –                        | –                          | –                    | +         | –                      | –                    | –                    |
| Markers of neurodegeneration | –                               | +                          | –                        | –                        | –                          | –                    | +         | –                      | +                    | –                    |

PLAD Project of Longevity and Aging in Dujangyan

\(\text{a}\) Including the cohorts recruited in 1895, 1905, 1910 and 1915, data availability varies per cohort. \(\text{b}\) Inflammation and senescence markers (for example p16, p53 and telomere associated foci)
| Domain                      | Potential protective factor | Study                        | Age<sup>a</sup> | Sample size (N) | Outcome variable | Result          |
|-----------------------------|-----------------------------|------------------------------|-----------------|-----------------|-----------------|-----------------|
| Cognitve reserve            | High level of education     | H85 Gothenburg study [18]    | 85.7 (±0.05)    | No dementia: 794 | Dementia        | Protective      |
|                             |                             | The 90+ Study [4]             | 94 (90–106)     | No dementia: 536 | Dementia        | Protective      |
|                             |                             | Vantaa 85+ Study [17]         | 88.4 (85.0–104.0)| No incident dementia: 239 | Incident dementia: 100 | Protective |
|                             |                             |                             |                 |                  | Incidence dementia |                 |
|                             |                             |                              |                 |                  | Dementia         | Equivocal       |
| High cognitive activity     | The 90+ Study [16]           | 93 (90–103)                  | No incident dementia: 319 | Incident dementia: 268 | Incident dementia | Equivocal       |
| Vascular comorbidity        | Low total/low LDL or high HDL cholesterol level | Leiden 85–plus Study [20] | 85 (85) | No dementia: 488 | Dementia: 73 | Cognition Dementia | Equivocal |
|                             |                            | Newcastle 85+ Study [19]     | 85 (85)         | No dementia: 767 | Dementia: 78 | Cognition Dementia | Equivocal |
|                             |                            | Nona Santfeliu study [21]   | 94.3 (±2.6)     | 62, dementia status unknown |              | Cognition No effect |
|                             |                            | Octabaix study [22]          | 85 (85)         | 321, dementia status unknown |              | Cognition No effect |
|                             |                            | PLAD [15]                    | 93.6 (90–108)   | No cognitive impairment: 300 | Cognitive impairment: 409 | |
| Absence of hypertension    | Leiden 85–plus Study [23]   | 85 (85)                      | 572, dementia status unknown |              | Cognition Dementia | Risk |
|                             | Newcastle 85+ Study [19]    | 85 (85)                      | No dementia: 767 | Dementia: 78 | Cognition Dementia | Equivocal |
|                             | PLAD [27]                   | 93.6 (90–108)                | No cognitive impairment: 317 | Cognitive impairment: 465 |              | Cognition No effect |
| Umeå 85+ study [26]         | 85, 90 and ≥ 95             | No dementia: 342             | Dementia: 233 |          | Cognition Dementia | Protective |
| Umeå 85+ study [25]         | 88.8 (±4.1)                 | No incident dementia: 136    | Incident dementia: 69 |              | Incident dementia |                  |
| The 90+ Study [24]          | 93.2 (90–103)               | No incident dementia: 335    | Incident dementia: 224 |              | Incident dementia | Risk |
| Vantaa 85+ Study [17]       | 88.4 (85.0–104.0)           | No incident dementia: 239    | Incident dementia: 100 |              | Incident dementia | Equivocal |
| Absence of DM               | Leiden 85–plus Study [30]   | 85 (85)                      | 596, dementia status unknown |              | Cognition Dementia | Equivocal |
|                             | Octabaix study [31]         | 85 (85)                      | 167, dementia status unknown |              | Cognition Dementia | No effect |
|                             | Vantaa 85+ Study [11]       | 285                          | No incident dementia: 249 | Incident dementia: 106 |              | Protective      |
### Table 2: Potential protective factors for cognitive impairment in the oldest-old (Continued)

| Domain                  | Potential protective factor | Study                                                                 | Age$^a$       | Sample size (N) | Outcome variable | Result     |
|-------------------------|----------------------------|-----------------------------------------------------------------------|---------------|-----------------|------------------|------------|
| Absence of stroke       |                            | H85 Gothenburg study [18]                                             | 85.7 (±0.05)  | No dementia: 794 Dementia: 271 | Dementia         | Protective  |
|                         |                            | Vantaa 85+ Study [32]                                                 | 88.4 (±2.9)   | No dementia: 339 Dementia: 214 Incident dementia: 100 | Dementia         | Protective  |
| Absence of AF           |                            | Vantaa 85+ Study [32]                                                 | 88.4 (±2.9)   | No dementia: 339 Dementia: 214 Incident dementia: 100 | Dementia         | No effect   |
| Mood and sleep          | No depression              | Leiden 85-plus Study [34]                                             | 85 (85)       | 500, dementia status unknown | Cognition       | Protective  |
|                         |                            | Umeå 85+ study [14]                                                  | 85, 90 and 95–103 | No dementia: 173 Dementia: 69 | Dementia         | Protective  |
|                         | High sleep quality         | PLAD [35]                                                             | 93.5 (±3.4)   | No dementia: 251 Dementia: 409 | Dementia         | Protective  |
| Sensory system          | Absence of visual impairment | Leiden 85-plus Study [37]                                             | 85 (85)       | 459, dementia status unknown | Cognition       | Protective  |
|                         |                            | Newcastle 85+ Study [38]                                              | 85 (85)       | No dementia: 771 Dementia: 68 | Cognition       | Protective  |
|                         | Absence of glaucoma or cataract | Newcastle 85+ Study [105]                                           | 85 (85)       | No dementia: 771 Dementia: 68 | Cognition       | Equivocal   |
|                         | Absence of hearing impairment | Leiden 85-plus Study [37]                                             | 85 (85)       | 459, dementia status unknown | Cognition       | Equivocal   |
| Physical performance    | Good physical performance  | Leiden 85-plus Study [40]                                             | 85 (85)       | 555, dementia status unknown | Cognition       | Protective  |
| and capacity            |                            | The 90+ Study [41]                                                   | 93.3 (±2.6)   | No incident dementia: 366 Incident dementia: 212 | Incident dementia | Protective  |
|                         | High physical activity     | The 90+ Study [16]                                                   | 93 (90–103)   | No incident dementia: 319 Incident dementia: 268 | Incident dementia | No effect   |
| Genetics                | Absence of APOEε4 and/or presence of APOEε2 | Danish 1905 birth cohort [42]                                  | 93.1 (±0.3)   | 1551, dementia status unknown | Cognition       | No effect   |
|                         |                            | Leiden 85-plus Study [43]                                             | 89.0 (87.4–91.2)$^b$ | No dementia: 242 Dementia: 78 | Dementia         | Protective  |
|                         |                            | The 90+ Study [44]                                                   | 93.7 (90–105) | No dementia: 566 Dementia: 236 Incident dementia: 188 | Dementia         | Equivocal   |
|                         |                            | Vantaa 85+ Study [45]                                                 | 285           | 313 without dementia 197 with dementia | Dementia         | Protective  |
|                         |                            | Vantaa 85+ Study [46]                                                 | 285           | No incident dementia: 187 Incident dementia: 58 | Incident dementia | No effect   |
|                         | MnSOD, GLRX, GSTP1, MT1A, NDUFV1, PRDX3, UQCRFS1, PICALM | Danish 1905 birth cohort [106–108]                              | 92-93$^c$     | 1089–1650, dementia status unknown | Cognition       | Protective  |
|                         | ACOX1                      | Danish 1905 birth cohort [106]                                      | 93.2 (92.7–93.8) | 1089, dementia status unknown | Cognition       | Risk        |
|                         | Cytokine genes, CLU        | Danish 1905 birth cohort [108–110]                                  | 92-93$^c$     | 1380–1651, dementia status unknown | Cognition       | Equivocal   |
|                         | MTHFR, MTR                 | Danish 1905 birth cohort [111]                                      | 93.1 (±0.3)   | 1651, dementia status unknown | Cognition       | No effect   |
shown that the prevalence of amyloid aggregation increases with age in cognitively healthy subjects but decreases in the oldest-old subjects with dementia [1]. A similar trend can be seen with regard to amyloid \(\beta\) measured in CSF or on an amyloid PET scan [53, 54]. In subjects without dementia, greater amyloid load has been associated with poorer cognitive functioning and a higher rate of incident dementia, although the number of oldest-old subjects in these studies was limited [55–57]. There are a few studies that have related brain MRI measurements in the oldest-old to cognitive functioning. Less atrophy and fewer white matter hyperintensities were seen in subjects without dementia compared to subjects with dementia [58, 59] but white matter integrity was not related to cognition [60]. In younger subjects, neurophysiological measures on magnetoencephalography (MEG) have been related to dementia [61] but it is unknown whether this relationship persists in the oldest-old.

### Aims and objectives of the EMIF-AD 90+ study

The EMIF-AD 90+ Study was set-up to investigate the protective factors for cognitive impairment in the oldest-old. The study was part of the Innovative Medicine Initiative (IMI) European Medical Information Framework for AD (EMIF-AD) project (http://www.emif.eu/about/emif-ad) on diagnostic markers, prognostic markers, and protective factors for AD. The EMIF-AD 90+ study focuses on the extreme phenotype of the cognitively normal oldest-old. The primary objectives of the EMIF-AD 90+ study are:

i) To identify factors associated with resilience to cognitive impairment in the oldest-old.

### Table 2 Potential protective factors for cognitive impairment in the oldest-old (Continued)

| Domain                        | Potential protective factor | Study                                                                 | Age\(^a\) | Sample size (N) | Outcome variable | Result       |
|-------------------------------|-----------------------------|----------------------------------------------------------------------|-----------|----------------|-----------------|--------------|
| KLOTHO                        | PLAD [112]                  | 93.5 (90–108)                                                         | No cognitive impairment: 236 Cognitive impairment: 470 |
| PPAR-\(\gamma\)2              | PLAD [113]                  | 93.7 (90–108)                                                         | No cognitive impairment: 257 Cognitive impairment: 475 |
| LRP, LPL, ACE                 | Vantaa 85+ Study [114]      | 285                                                                 | No dementia: 203 Dementia (AD): 113 |
| Hallmarks of ageing Low level of inflammation markers | Leiden 85-plus Study [49] | 85 (85)                                                             | No dementia: 491 |
|                               | The 90+ Study [50]          | 94.3 (90–105)                                                         | No dementia: 232 Dementia: 73 |
|                               | The 90+ Study [51]          | 93.9 (90–102)                                                         | No incident dementia: 145 Incident dementia: 82 |
|                               | Low level of senescence markers | Leiden 85-plus Study [52]     | 89.8 (85–101) | No dementia: 452 Dementia: 146 Incident dementia: unknown |
|                               | Markers of neurodegeneration Normal levels of A\(\beta\) and tau in CSF | H85 Gothenburg study [56] | 85 (85) | No incident dementia: 28 Incident dementia: 7 |
|                               | Negative amyloid PET-scan   | The 90+ Study [57]                                                   | 94.2 (90–99)\(^d\) No incident dementia: 10 Incident dementia: 3 |
|                               | Less brain atrophy          | H85 Gothenburg study [58]                                            | 85 (85) | No dementia: 30 Dementia: 23 |
|                               | Less WMH                    | H85 Gothenburg study [59]                                            | 85 (85) | No dementia: 133 Dementia: 103 |
|                               | High white matter integrity | The 90+ Study [60]                                                   | 94.6 (90–103) Normal: 64 CIND: 30 |

\(\text{A}\!\beta\) Amyloid \(\beta\), \(\text{AD}\) Alzheimer’s disease, APOE Apolipoprotein E, CIND Cognitive Impairment, No Dementia, CSF cerebrospinal fluid, DM diabetes mellitus, HDL high-density lipoproteins, LDL low-density lipoproteins, MCI Mild Cognitive Impairment, MMSE Mini-Mental State Examination, N Number, PET positron emission tomography, PLAD Project of Longevity and Aging in Dujangyan, WMH white matter hyperintensities

\(^a\) Mean age (range, if available, or \(\pm\) if standard deviation) in years at baseline, unless stated otherwise; \(^b\) Median age (interquartile range, IQR) in years; \(^c\) Minimal and maximum mean age in years of the studies referred to; \(^d\) Median age (range) in years
ii) To test the relationship between hallmarks of aging and cognitive impairment in the oldest-old.

iii) To test the relationship between markers of neurodegeneration and cognitive impairment in the oldest-old.

This paper describes the design and protocol of the study.

**Methods**

**Study subjects**

We aimed to include 80 cognitively normal subjects and 40 subjects with cognitive impairment, both aged 90 years and older. Inclusion criteria for cognitively normal subjects were a global Clinical Dementia Rating (CDR) score of 0 [62] and a score ≥ 26 points on the Mini-Mental State Examination (MMSE) [63]. Inclusion criteria for subjects with cognitive impairment were a diagnosis of amnestic MCI (aMCI) [64] or a diagnosis of probable or possible AD [65] by a neurologist, geriatrician, or general practitioner, a global CDR score ≥ 0.5 point (s) and a MMSE score of 20–28 points (inclusive). Exclusion criteria were the physical inability to undergo the procedures, visual or hearing impairment which made neuropsychological testing impossible, severe depression (Geriatric Depression Scale (GDS) score ≥11 points [66]) and other comorbidities or medication that could impair cognition at the discretion of the investigator (e.g. stroke, epilepsy or use of lithium carbonate). During the inclusion period it turned out to be difficult to identify subjects of 90 years and older with aMCI or probable or possible AD; we therefore broadened the inclusion criteria in this group to subjects older than 85 years.

Subjects were recruited at two sites: the Amsterdam UMC, The Netherlands and The University of Manchester, United Kingdom. Cognitively normal subjects were recruited from general practitioners or via advertisements (Amsterdam) or from the Manchester and Newcastle Ageing Study (MNAS, Manchester). Subjects with cognitive impairment were only recruited in the Netherlands. They were recruited from the Alzheimer Center Amsterdam and the Center Of Geriatric medicine Amsterdam (COGA) at the Amsterdam UMC, geriatric departments of other hospitals in the surroundings of Amsterdam, other healthcare facilities (such as a care home), general practitioners or via advertisement. The sample collection started on the 1st of June 2016 and ended on the 30th of June 2018. Currently we are working on the first data analyses.

The Medical Ethics Review Committee of the Amsterdam UMC approved the study in Amsterdam and the National Research Ethics Service Committee North West - Greater Manchester South performed approval of the study in Manchester. The study was carried out in accordance with the ethical conduct and juridical laws of the Declaration of Helsinki 64th WMA General Assembly, Fortaleza, Brazil, October 2013, (www.wma.net), and in accordance with the Medical Research Involving Human Subjects Act (WMO). All subjects gave written informed consent.

**Study design**

The EMIF-AD 90+ Study is a case-control study in which we search for protective factors for cognitive impairment. Therefore, the cognitively normal subjects are described as cases and the subjects with cognitive impairment as controls.

**Study procedures**

The study consisted of two home visits and one or two visits at the hospital/clinical research facility (CRF). During the first home visit, in- and exclusion criteria (MMSE, CDR, impression of physical ability to undergo the procedures, hearing and visual abilities) were verified, in addition to collection of first study data (Table 3, paragraphs 2.3.1, 2.3.2 and 2.3.4). The MMSE is a short cognitive screening test with a maximum score of 30 points [63]. The CDR is a scale for the severity of symptoms of dementia, which was assessed by interviews with the subject and, if available, study partner (somebody that is in regular contact with the subject) in combination with judgement by the researchers [62]. The second home visit consisted of a neuropsychological assessment performed by a neuropsychologist (paragraph 2.3.3). During the hospital/CRF visits several procedures were performed, which are listed in Table 3 and described in paragraphs 2.3.4. – 2.3.10. These procedures provided information on i) potential protective factors (classified in six different domains), ii) hallmarks of aging, and iii) markers of neurodegeneration (Fig. 1 and Table 3). For each domain, hallmark of aging or markers of neurodegeneration, we will test one or more parameters (Table 3). In most cases, all procedures were performed within three months from start of the inclusion. Any differences in study procedures between Amsterdam and Manchester are explicitly stated in this paper.

**Interview**

Data about the medical and family history, medication use, education and intoxications (alcohol use and smoking) were collected through a structured interview, in combination with information provided by the study partner (if available), general practitioner and/or medical specialist.

**Questionnaires**

In Amsterdam, subjects were asked to complete six questionnaires. Activities of daily living (ADL) were evaluated by use of the Katz ADL [67]. Functional health
and wellbeing were evaluated by the Short form-12 Health-related Quality of Life (SF-12 HRQoL) questionnaire [68] and by the Cognitive Complaints Index (CCI) [69]. Nutrition was evaluated by the Mini Nutritional Assessment (MNA-long version) [70]. Sleep disorders were evaluated by use of the Berlin Questionnaire which identifies the risk of sleep disordered breathing [71]. Cognitive activity during life, such as reading books and playing games, was assessed with the cognitive abilities questionnaire [72]. Subjects with cognitive impairment filled in the questionnaires together with a study partner. The GDS was filled in together with the researcher [66].

Table 3 The domains of interest in the EMIF-AD 90+ Study

| Domain                             | Parameter                           | Procedure (measurement)          | Schedule Amsterdam | Schedule Manchester |
|-----------------------------------|-------------------------------------|----------------------------------|--------------------|---------------------|
| Cognitive reserve                 | Level of education                  | Interview                        | Home               | Home                |
| Cognitive activity                |                                     | Cognitive abilities questionnaire | Home               | Home                |
| Vascular comorbidity              | Cholesterol level, hypertension, DM, stroke, AF | Blood collection                | Hospital           | WMIC                |
|                                   |                                     | Medical history and medication use | Home               | Home                |
|                                   |                                     | Blood pressure                   | Hospital           | CRF                 |
|                                   |                                     | Diagnostick/heart rate           | Home               | CRF                 |
|                                   |                                     | Ultrasound carotid artery        | Hospital           | CRF                 |
| Mood and sleep                    | Depressive symptoms                 | Geriatric Depression Scale       | Home               | Home                |
|                                   | Sleep disorder                      | Berlin Questionnaire and MSQ     | Home               | Home                |
|                                   |                                     | Accelerometer (sleep quality)    | Home               | N/A                 |
| Sensory system                    | Visual acuity                       | ETDRS chart                      | Hospital           | N/A                 |
|                                   | Retinal thickness                   | OCT                              | Hospital           | N/A                 |
|                                   | Auditory function                   | Digits-in-noise test             | Home               | N/A                 |
|                                   | Olfactory function                  | Sniffin sticks                   | Hospital           | N/A                 |
| Physical performance and capacity | Physical performance                | Grip strength                    | Home               | CRF                 |
|                                   |                                     | Short Physical Performance Battery or 4-min walking test | Hospital           | CRF                 |
|                                   |                                     | BIA (muscle mass)                | Hospital           | N/A                 |
|                                   | Physical activity                   | Accelerometer                    | Home               | N/A                 |
| Genetics                          | APOEe4 and APOEe2                    | Blood collection                 | Hospital           | WMIC                |
| Hallmarks of ageing               | Level of inflammation markers       | Blood collection (i.a. PBMCs)    | Hospital           | WMIC                |
|                                   | Level of senescence markers         | Skin biopsy (senescence markers p16, p53 and telomere associated foci) | Hospital           | N/A                 |
|                                   | Nutritional status                  | BIA                              | Hospital           | N/A                 |
|                                   |                                     | Blood collection                 | Hospital           | CRF                 |
|                                   |                                     | BMI                              | Hospital           | CRF                 |
|                                   |                                     | MNA                              | Home               | N/A                 |
| Markers of neurodegeneration      | Aβ1–42 and tau in CSF and blood     | CSF collection                   | Hospital           | N/A                 |
|                                   | Amyloid PET scan                    | Amyloid PET scan                 | Hospital           | WMIC                |
|                                   | Brain atrophy                       | Brain MRI scan or brain CT scan  | Hospital           | CRF                 |
|                                   | WMH                                 | Brain MRI scan or brain CT scan  | Hospital           | CRF                 |
|                                   | White matter integrity              | Brain MRI scan                   | Hospital           | N/A                 |
|                                   | Brain connectivity                  | Brain MRI scan                   | Hospital           | CRF                 |
|                                   |                                     | MEG                              | Hospital           | N/A                 |

Aβ Amyloid β, AD Alzheimer’s disease, AF atrial fibrillation, APOE Apolipoprotein E, BIA Bioelectrical impedance analysis, BMI Body Mass Index, CRF Clinical Research Facility, CT Computerized Tomography, CSF cerebrospinal fluid, DM diabetes mellitus, ETDRS Early Treatment Diabetic Retinopathy Study, MEG magnetoencephalography, MNA Mini Nutritional Assessment, MRI Magnetic Resonance Imaging, MSQ Mayo Sleep Questionnaire, N/A not applicable, OCT Optical Coherence Tomography, PBMCs Peripheral Blood Mononuclear Cells, PET positron emission tomography, PLAD Project of Longevity and Aging in Dujangyan, WMH white matter hyperintensities, WMIC Wolfson Molecular Imaging Centre
In Amsterdam, the study partner was asked to complete five questionnaires: the AD8 (an 8-question test for the study partner to assess mild dementia) [73], the Amsterdam instrumental Activities of Daily Living (iADL) scale (a study partner based tool aimed at detecting iADL problems in early dementia) [74, 75], the Neuropsychiatric Inventory Questionnaire (NPI-Q, to assess the severity of behavioral symptoms in the subject and the distress these symptoms cause in the study partner) [76], the Mayo Sleep Questionnaire (MSQ, to screen for the presence of Rapid Eye Movement (REM) sleep disorders) [77], and finally the CCI [69].

In Manchester, subjects were asked to complete the SF-12 HRQoL questionnaire [68], the Physical Activity Scale for the Elderly (PASE) [78], the CCI [69] and the cognitive abilities questionnaire [72]. The study partner was asked to complete the AD8 [73], the Functional Activities Questionnaire (FAQ) [79] and the CCI [69].

Neuropsychological assessment
The neuropsychological assessment took approximately one and a half hours during which several cognitive domains were tested. Table 4 gives an overview of the different cognitive tests that were administered, which domain they examine and at which site they were performed.

Physical examination
In Amsterdam, data on waist and hip circumference (cm), and hand grip strength (kg), as well as a standard neurologic screening examination were recorded during the first home visit. Hand grip strength was measured to estimate muscle strength and was performed with a hand dynamometer (Jamar hand dynamometer; Sammons Preston, Inc., Bolingbrook, IL., USA) [80]. In addition, a ‘Diagnostick’ was used to determine whether the subject had atrial fibrillation by measuring one derivative of an electrocardiogram [81]. At the end of the first home visit, the subject was asked to wear an accelerometer (DynaPort MoveMonitor, McRoberts B.V., The Hague, The Netherlands) for seven days to measure physical activity and sleep quality.

During the hospital visit in Amsterdam, continuous blood pressure measurements were performed non-invasively using a digital photoplethysmogram on the right middle finger (Nexfin®, BMEYE, Amsterdam, The Netherlands), resulting in beat-to-beat BP data. The Short Physical Performance Battery (SPPB) included balance tests, a 4 m walk to measure walking speed and the chair stand test [82]. Body composition, including the Body Mass Index (BMI), was measured using a Bioelectrical Impedance Analysis (BIA; InBody 770; Biospace Co., Ltd., Seoul, Korea).

In Manchester, waist and hip circumference (cm), hand grip strength (kg), BMI, resting blood pressure, heart rate, ankle/brachial pressure index [83] and a 4 min walking test were recorded at the clinical research facility.

Sensory system
Measurements of the sensory system were only performed in Amsterdam. With regard to visual functioning, best corrected visual acuity was tested with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Intra-Ocular Pressure (IOP) and refraction data of all subjects were obtained, and all subjects underwent slit lamp examination and indirect fundoscopy. Pupils were dilated using tropicamide 0.5% and phenylephrine 5%. Peripapillary Retinal Nerve Fiber Layer (pRNFL) thickness and macular (layer) thickness were measured with Spectral Domain Optical Coherence Tomography (SD-OCT, Heidelberg Spectralis) using Heidelberg’s build-in software [84]. With enhanced depth imaging,
the choroid was imaged and its thickness was (manually) measured. With fundus photography (Topcon TRC 50DX type IA), we acquired digital fundus images (50°). From these, seven Retinal Vascular Parameters (RVPs) were obtained using Singapore I Vessel Assessment (SIVA, version 3.0) [85].

For the auditory function, we used the digits-in-noise (DIN) test [86]. The DIN test is a speech-in-noise test using digit triplets as speech material. The digit triplets are presented against a constant level of stationary background noise. The test uses an adaptive procedure to determine the signal-to-noise ratio at which a listener understands 50% of the digit triplets correctly (i.e. the speech reception threshold (SRT) in noise). Olfactory function was measured using “Sniffin’ Sticks” (Burghart, Wedel, Germany). The test consists of pen-like odor dispensing devices with odors that are considered to be familiar. The smell test in the present study contained the odor identification part of the test [87].

### Blood collection and skin biopsy

In both centers, blood samples were collected according to the biobanking pre-analytical Standard Operating Procedures (SOPs) of the Biomarkers for Alzheimer’s disease and Parkinson’s disease (BIOMARKAPD) project [88]. Blood samples were collected for DNA and RNA analysis, inflammation markers, proteomics, neurodegenerative markers (amyloid β, tau, neurofilament light), routine blood analysis (i.e. lipids and glucose), vitamin status (B12 and folic acid) and, in Amsterdam only, for Peripheral Blood Mononuclear Cells (PBMCs). Planned DNA analysis includes Single Nucleotide Polymorphisms (SNP) analysis of known genetic risk factors for AD or amyloid pathology [89–92]. DNA and RNA isolation will

---

**Table 4 Cognitive tests in the EMIF-AD 90+ Study**

| Cognitive test | Cognitive domain | Site |
|---------------|------------------|------|
| CERAD 10 words test [115] | Immediate recall | B$^a$ |
| Logical Memory test [116] | Immediate recall | A |
| Rey Auditory Verbal Learning Test [117] | Immediate recall | M |
| Rey Complex Figure Test [118] | Copy | B |
| WAIS-III Digit span forward and backward [119, 120] | | |
| Animal (2 min) and Letter fluency (1 min per letter$^b$) [121] | | |
| Clock Drawing Test$^c$ [122] | | |
| Graded Naming Test [123] | | |
| Trail Making Test A and B [124] | | |
| WAIS-R Digit Symbol Substitution Test [125] | | |
| Computerised Cambridge Neuropsychological Test Automated battery [126] | | |
| National Adult Reading Test [127] | | |
| Visual Association Test [128] | | |
| Addenbrooke’s Cognitive Examination Revised battery [129] | | |

$\text{A}^{}$ administered only in Amsterdam, $\text{B}^{}$ administered in Amsterdam and Manchester, CERAD Consortium to Establish a Registry for Alzheimer’s Disease, $\text{M}^{}$ administered only in Manchester, $\text{min}^{}$ minute (s), WAIS (−R) Wechsler Adult Intelligence Scale (−Revised)

$^a$In Manchester only in the cognitively normal subjects. $^b$In Amsterdam using the letters D, A and T and in Manchester the letters F, A, and S. $^c$The subject will be asked to draw a clock showing the time “ten after eleven”. In total 14 points can be scored based on the presence and sequencing of the numbers and the positioning of the two hands.
be performed by EMIF-AD partners. Remaining samples will be stored for future biomarker identification and validation studies.

In Amsterdam, four millimeter skin biopsies were taken from the inner upper medial arm and will be stained for senescence markers p16, p53 and telomere associated foci.

**Cerebrospinal fluid collection**

In Amsterdam, up to 20 mL CSF was obtained by lumbar puncture in Sarstedt polypropylene syringes using a Spinocan 25 Gauge needle in one of the intervertebral spaces between L3 and S1. A half mL CSF was immediately processed for leukocyte count, erythrocyte count, glucose, and total protein. The remaining CSF was mixed and centrifuged at 1300–2000 × g at 4 °C for ten minutes. Supernatants were stored in aliquots of 0.25–0.5 mL and frozen within two hours at −80 °C and stored for future biomarker discovery studies. The processing and storing of CSF was performed according to the BIOMARKAPD SOP [88]. Amyloid β 1–42, total tau and phosphorylated tau 181 will be analyzed in a single batch. Remaining samples will be stored for future biomarker identification and validation studies.

**Ultrasound carotid artery**

At both sites, a duplex ultrasound scan of the carotid artery was performed. In Amsterdam, the right carotid artery was scanned to assess intima media thickness and distension using ArtLab software [93, 94]. In Manchester, left and right carotid arteries were scanned to determine velocity, vessel thickness, stenosis and plaques, rated according to the North American Symptomatic Carotid Endarterectomy Trial guidelines [95].

**Brain MRI scan**

Subjects underwent locally optimized brain MRI protocols including 3D-T1, fluid attenuated inversion recovery (FLAIR), susceptibility weighted imaging (SWI), diffusion tensor imaging (DTI) and resting state functional MRI (rs-fMRI). MRI scans were performed on Philips 3 T Achieva scanners. Additionally, in Manchester regional cerebral blood flow was measured by arterial spin labelling [96], but no DTI scan was acquired in Manchester. In Amsterdam, if a subject could not undergo the MRI scan, we considered a CT scan (Phillips Ingenuity TF or Gemini TF camera). Scans will be analyzed locally and centrally by EMIF-AD partners using the Neugrid infrastructure if applicable (see Additional file 1).

**Amyloid PET scan**

[18F] Flutemetamol, a specific fibrillary amyloid β radiotracer, was used for the amyloid PET scans. In Amsterdam, [18F] flutemetamol was produced by General Electric (GE) Healthcare at the Cyclotron Research Center of the University of Liège (Liège, Belgium) and PET scans were performed using a Philips Ingenuity TF PET-MRI scanner (Philips Medical Systems, Cleveland, Ohio, USA) or, in case of a PET-CT scan, the Philips Ingenuity TF (Philips Medical Systems, Best, the Netherlands) or Gemini TF scanner (Philips Medical Systems, Best, the Netherlands). In Manchester, [18F] flutemetamol was produced at the Wolfson Molecular Imaging Centre (WMIC)’s Good Manufacturing Practice radiochemistry facility using GE Healthcare’s FASTlab and cassettes and PET scans were performed using a High Resolution Research Tomograph (HRRT; Siemens/CTI, Knoxville, TN). In both centers, the emission scan was performed in two parts. First a 30 min dynamic emission scan was started simultaneously with a bolus intravenous injection of 185 MBq [18F] flutemetamol. The second part of the scan was performed from 90 to 110 min post injection. In Amsterdam, immediately before each part of the PET scan a T1-weighted gradient echo pulse MRI or low dose CT scan was obtained. This MRI or CT scan was used for attenuation correction of the PET scan. In Manchester, two seven minute transmission scans, one before the first emission scan and the other after the second emission scan, using a 137Cs point source were acquired for subsequent attenuation and scatter correction.

All [18F] flutemetamol scans were read visually as positive or negative. Additionally, we determined time activity curves for each region of interest with cerebellum grey matter as input function [97]. The dynamic data were analyzed on a voxel-by-voxel level using the Simplified Reference Tissue Model 2 (SRTM2) [98, 99]. Finally, we investigated tracer uptake by using a simplified method: the standardized uptake value ratio (SUVr, target to grey matter cerebellum SUV over 90–110 min pi) [100]. Variability in acquisition of amyloid PET scans were reduced by harmonizing acquisition protocols and will be reduced by adding it to the analyses as a covariate.

**Neurophysiology**

In Amsterdam, MEG was performed using a 306 channel whole-head system (Elekta Neuromag Oy, Helsinki, Finland). Eyes-closed and eyes-open resting-state MEG data were recorded with subjects in supine position inside a magnetically shielded room. We will use transformed time series [101] to extract spectral properties (relative band power and peak frequency) [102], and estimates of functional connectivity between brain regions, and metrics that characterize the topology of the functional brain networks [103, 104]. These analyses will be applied using Elekta’s beamformer software, and both in-house developed Matlab tools and BrainWave software (http://home.kpn.nl/stam7883/brainwave.html).
Planned statistical analyses
For each parameter listed in Table 3, we will test with logistic regression models whether it is associated with resilience to cognitive impairment. In addition, linear regression models will be used to associate the same parameters with cognitive functioning in the total sample. Potential additional analyses include the identification of protective factors for abnormal AD biomarkers in the subsample of cognitively normal subjects and the identification of protective factors for cognitive impairment in subjects with a high risk, for example APOE e4 carriers.

Discussion
We described the design of the EMIF-AD 90+ Study that aims to unravel the factors associated with resilience to cognitive impairment in the oldest-old. An important additional value of the EMIF-AD 90+ Study compared to the previous studies is the extensive phenotyping of subjects, which includes data about cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity and genetic risk factors. Furthermore, the EMIF-AD 90+ Study is one of the first studies that collects a broad range of markers of neurodegeneration in the oldest-old, including an amyloid PET scan, amyloid β and tau measured in CSF and blood and neurophysiological measures.

The EMIF-AD 90+ is the first study worldwide that combines data regarding the hallmarks of aging with markers of neurodegeneration. The process of aging and the incidence of aMCI and possible or probable AD are very much interrelated. Our study allows to test hypotheses such as that common risk factors and pathways drive both the aging process and development of cognitive impairment or AD. Another strength of the EMIF-AD 90+ study is that we use objective measures wherever possible, instead of using questionnaires. For example, physical activity and sleep quality were measured with an accelerometer in Amsterdam.

To conclude, the results of the EMIF-AD 90+ Study will provide an important contribution to the existing literature in many different ways. It will extend our knowledge on protective factors for cognitive impairment in the oldest-old and will determine how hallmarks of aging and markers of neurodegeneration relate to cognitive impairment in this specific age group.

Additional file

Additional file 1: Table S1. Brain MRI scan analyses in the EMIF-AD 90+ Study. (DOCX 26 kb)

Abbreviations
ACE-R: Addenbrooke’s Cognitive Examination Revised; AD: Alzheimer’s disease; ADL: Activities of daily living; Amsterdam UMC: Amsterdam University Medical Centers; APOE: Apolipoprotein E; Aβ: Amyloid β; BIA: Bioelectrical Impedance Analysis; BIOMARKAPD: Biomarkers for Alzheimer’s disease and Parkinson’s disease; BMI: Body Mass Index; CANTAB: Cambridge Neuropsychological Test Automated battery; CCI: Cognitive Complaints Index; CDR: Clinical Dementia Rating; CERAD: Consortium to Establish a Registry for Alzheimer’s Disease; COGA: Center Of Geriatric medicine Amsterdam; CSF: cerebrospinal fluid; DIN test; digits-in-noise test; DSST: Digit Symbol Substitution Test; DTI: diffusion tensor imaging; EMIF-AD: European Medical Information Framework for AD; ETDRS: Early Treatment Diabetic Retinopathy Study; FLAIR: fluid attenuated inversion recovery; GDS: Geriatric Depression Scale; GE: General Electric; GNT: Graded Naming Test; HRRT: High Resolution Research Tomograph; iADL: instrumental Activities of Daily Living; IMI: Innovative Medicine Initiative; IOP: Intra-Ocular Pressure; MEG: magnetoencephalography; MMSE: Mini-Mental State Examination; MNA: Mini Nutritional Assessment; MNAS: Manchester and Newcastle Aging Study; MSQ: Mayo Sleep Questionnaire; N/A: not applicable; NART: National Adult Reading Test; NPI-Q: Neuropsychiatric Inventory Questionnaire; OCT: Optical Coherence Tomography; PKSE: Physical Activity Scale for the Elderly; PBMCs: Peripheral Blood Mononuclear Cells; PET: positron emission tomography; PLAD: Project of Longevity and Aging in Dujangyan; pRNFL: peripapillary Retinal Nerve Fiber Layer; RAVLT: Rey Auditory Verbal Learning Test; RCFT: Rey Complex Figure Test; REM: Rapid Eye Movement; r-fMRI: resting state functional MRI; RVPs: Retinal Vascular Parameters; SD-OCT: Spectral Domain Optical Coherence Tomography; SF-12 HRQoL: Short form 12 Health-related Quality of Life; SIVA: Singapore I vessel Assessment; SNP: Single Nucleotide Polymorphisms; SOP: Standard Operating Procedure; SPPR: Short Physical Performance Battery; SRT: speech reception threshold; SRTM2: Simplified Reference Tissue Model 2; SUVr: standardized uptake value ratio; SWI: susceptibility weighted imaging; TMT: Trail Making Test; VAT: Visual Association Test; WAIS: Wechsler Adult Intelligence Scale; WMMH: white matter hyperintensities

Acknowledgements
We very much acknowledge all subjects who participated in the EMIF-AD 90+ Study.

Funding
The EMIF-AD 90+ Study was funded by the EU/EFPIA Innovative Medicines Initiative Joint Undertaking Emif grant agreement no. 115372. FB is supported by the NIHR UCLH biomedical research centre.

Availability of data and materials
Data collected in the EMIF-AD 90+ Study will be available through the EMIF-AD portal.

Ethics approval and consent to participate
The Medical Ethics Review Committee of the Amsterdam UMC approved the study in Amsterdam (reference number: 2015.374) and the National Research Ethics Service Committee North West - Greater Manchester South performed approval of the study in Manchester (reference number: 14/NW/0011). All subjects gave their written informed consent in accordance with the ethical conduct and juridical laws of the Declaration of Helsinki 64th WMA General Assembly, Fortaleza, Brazil, October 2013, (www.wma.net), and in accordance with the Medical Research Involving Human Subjects Act (WMO).

Consent for publication
Not applicable.

Competing interests
PJV is a Section Editor for BMC Geriatrics. None of the other authors reports any conflicts of interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, PO Box 7057, 1007, MB, Amsterdam, the Netherlands. "Wolfson Molecular Imaging Centre, Division of Neuroscience & Experimental Psychology, University of
Manchester, Manchester, UK. 1Department of Ophthalmology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 2Department of Geriatric Medicine, Spaarne Gasthuis, Haarlem, The Netherlands. 3Department of Internal Medicine, Amstelland Hospital, Amstelveen, The Netherlands. 4Department of Psychiatry, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 5Department of Geriatric Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. 6Department of Geriatric Medicine, MC Slotervaart Hospital, Amsterdam, The Netherlands. 7Department of Geriatric Medicine, Jeroen Bosch Hospital, ’s-Hertogenbosch, The Netherlands. 8Teva Pharmaceuticals, North Wales, Pennsylvania, USA. 9Janzen Pharmaceutical Research and Development, Titusville, NJ, USA. 10Boehringer Ingelheim International GmbH, Ingelheim/Rhein, Germany. 11Department of Internal Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 12Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 13Department of Clinical Neurophysiology and MEG Center, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam UMC, Amsterdam, The Netherlands. 14Department of Otolaryngology-Head and Neck Surgery, Section Ear & Hearing, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 15Department of Neurology, University College London, London, UK. 16Dutch Connectome Lab, Department of Complex Trait Genetics, Center for Neuroscience and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 17Department of Otolaryngology-Head and Neck Surgery, Section Ear & Hearing, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 18Department of Neurology, University College London, London, UK. 19Department of Medicine and Aged Care, @AgeMelbourne, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia. 20Department of Human Movement Sciences, @AgeAmsterdam, Amsterdam Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 21Department of Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.

Received: 15 June 2018 Accepted: 15 November 2018
Published online: 26 November 2018

References
1. Bullian SS, Corrada MM. Dementia in the oldest old. Continuum (Minneap Minn). 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
2. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
3. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
4. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
5. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
6. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
7. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
8. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
9. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
10. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
11. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
12. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
13. Rivard R, Charron C, Trone J-C, Falk AT, Guy J-B, Legdeur J, et al. Engineering, University College London, London, UK. 2013;19:457–69. https://doi.org/10.1212/01.CONN.0000429712278153.
72. Landau SM, Marks SM, Morrow EC, Rabnowicz GD, OH H, O’Neill JP, et al. Association of Lifetime Cognitive Engagement and low β-amyloid deposition. Arch Neurol. 2011;68:963–9.

73. Galvin JE, Roe CM, Poirier KK, Coats MA, Muche SJ, Grant E, et al. The AD8: a brief informant interview to detect dementia. Neurol. 2005;65:559–64. https://doi.org/10.1212/01.wnl.0000172958.95282.2a.

74. Siikonen S, Knol DL, Piirainen Y, van Lange-de Klerk ES, Uitdehaag BM, Scheltens P. Validation of the Amsterdam IADL questionnaire©, a new tool to measure instrumental activities of daily living in dementia. Neuroepidemiology. 2013;41:35–41. https://doi.org/10.1155/2013/462777.

75. Jutten RJ, Peeters CTW, Leijdesdorff SMJ, Visser PJ, Maier AB, Tenwee CB, et al. Detecting functional decline from normal aging to dementia: development and validation of a short version of the Amsterdam IADL questionnaire. Alzheimer’s Dementia Diagnosis. Assess Dis Monit. 2017;8:32–35. https://doi.org/10.1016/j.dadm.2017.03.002.

76. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NFQI, a brief clinical form of the neuropathologic inventory of the neuropsychiatric. J Neuropsychiatry Clin Neurosci. 2000;12:213–9. https://doi.org/10.1176/jnp.12.3.2133.

77. Boeve BF, Molano JR, Ferman TJ, Smith GE, Lin S-C, Bieniek K, et al. The Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011;12:445–53. https://doi.org/10.1016/j.sleep.2010.12.009.

78. Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46:153–62.

79. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of retinal nerve fiber layer segmentation on FD-OCT scans of normal subjects and glaucoma patients. JAMA Ophthalmol. 2013;131:1092–9. https://doi.org/10.1001/jamaophthalmol.2013.503.

80. Tielema RK, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, et al. Validation and clinical utility of a novel diagnostic device for screening of atrial fibrillation. Europace. 2014;16:1291–5. https://doi.org/10.1093/europace/euu057.

81. Gualtieri JM, Femurc L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556–62.

82. Al-Qaisi M, Nott DM, King DH, Kaddoura S. Ankle brachial pressure index (ABPI): an update for practitioners. Vasc Health Risk Manag. 2009;5:833–44. https://doi.org/10.2147/VHRM.S6759.

83. Al-Qaisi M, Nott DM, King DH, Kaddoura S. Ankle brachial pressure index (ABPI): an update for practitioners. Vasc Health Risk Manag. 2009;5:833–44. https://doi.org/10.2147/VHRM.S6759.

84. Mayer MA, Hornegger J, Mardin CY, Tornow RP. Retinal nerve fiber layer segmentation on FD-OCT scans of normal subjects and glaucoma patients. JAMA Ophthalmol. 2013;131:1092–9. https://doi.org/10.1001/jamaophthalmol.2013.503.

85. Jimenez-Soto RC, Perez AL. Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer’s disease. J Alzheimers Dis. 2014;42(Suppl 4):S411–9. https://doi.org/10.3233/JAD-141467.

86. Lammertse AA, Hume SP. Simplified reference region model for FDG-PET in Alzheimer’s disease. Neuroimage. 1996;4:153–5. https://doi.org/10.1016/1053-8119(96)00066-9.

87. Gunhild RN, Lammertse AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279–87. https://doi.org/10.1016/s0967-5549(96)00030-3.

88. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22:1440–52.

89. Vandenberghen R, Van Laere K, Ivanovu A, Salmon E, Batin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29. https://doi.org/10.1002/ana.22068.

90. Hillebrand A, Barnes GR, Bosboom JL, Berendse HW, Stam CJ. Frequency-dependent functional connectivity within resting-state networks: an atlas-based MEG beamformer solution. Neuroimage. 2012;59:3909–21. https://doi.org/10.1016/j.neuroimage.2011.11.005.

91. Fernández A, Hornero R, Mayo A, Paiva J, Gil-Gregorio P, Ortiz T. MEG spectral profile in Alzheimer’s disease and mild cognitive impairment. Clin Neurophysiol. 2006;117:306–14. https://doi.org/10.1016/j.clinph.2005.10.017.

92. de Haan W, van der Flier WM, Koene T, Smits LL, Scheltens P, Stam CJ. Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer’s disease. Neuroimage. 2012;59:8685–93.

93. Stam CJ. Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders. J Neurol Sci. 2010;289:128–34.

94. Jefferis JM, Taylor JP, Collerton J, Jagger C, Kingston A, Davies K, et al. The association between diagnosed glaucoma and cataract and cognitive performance in very old people: cross-sectional findings from the Newcastle 85+ study. Ophthalmic Epidemiol. 2013;20:82–8. https://doi.org/10.3109/09286586.2012.757626.

95. Dato S, Soerensen M, Lagani V, Montesanto A, Passaro G, Christensen K, et al. Contribution of genetic polymorphisms on functional status at very old age: a gene-based analysis of 38 genes (31 SNPs) in the oxidative stress pathway. Exp Gerontol. 2014;52:23–9. https://doi.org/10.1016/j.exger.2014.01.014.

96. Soerensen M, Christensen K, Stevnsner T, Christiansen L. The Mn-superoxide dismutase single nucleotide polymorphism rs4880 and the glutathione peroxidase 1 single nucleotide polymorphism rs1050450 are associated with aging and longevity in the oldest old. Mech Ageing Dev. 2009;130:308–14. https://doi.org/10.1016/j.mad.2009.01.005.

97. Mengel-From J, Christiansen K, McGuire M, Christiansen L. Genetic variations in the CLU and PICALM genes are associated with cognitive function in the oldest old. Neurobiol Aging. 2011;32:547–e7. https://doi.org/10.1016/j.neurobiolaging.2010.07.016.

98. Dato S, Krabbe KS, Thinggaard M, Pedersen BK, Christiansen K, Bruunsgaard H, et al. Commonly studied polymorphisms in inflammatory cytokine genes show only minor effects on mortality and related risk factors in nonagenarians. J Gerontol A Biol Sci Med Sci. 2011;66:525–33. https://doi.org/10.1093/gerona/glr210.

99. Mengel-From J, Thinggaard M, Lindahl-Jacobson R, McGuire M, Christiansen K, Christiansen L. CLU genetic variants and cognitive decline among elderly and oldest old. PLoS One. 2013;8:e79105. https://doi.org/10.1371/journal.pone.0079105.
111. Bathum L, von Bornemann HJ, Christiansen L, McGue M, Jeune B, Christensen K. Methylenetetrahydrofolate reductase 677C>T and methionine synthase 2756A>G mutations: no impact on survival, cognitive functioning, or cognitive decline in nonagenarians. J Gerontol A Biol Sci Med Sci. 2007;62:196–201.

112. Hao Q, Ding X, Gao L, Yang M, Dong B. G-395A polymorphism in the promoter region of the KLITOH gene associates with reduced cognitive impairment among the oldest old. Age (Omaha). 2016;38:1–8. https://doi.org/10.1007/s11357-015-9869-7.

113. Ji-Rong Y, Bi-Rong D, Chang-Quan H, Zhen-Chan L, Hong-Mei W, Yan-Ling Z. Pro12Ala polymorphism in PPAR-γ and dementia in Chinese nonagenarians/centenarians. Age (Omaha). 2010;32:397–404. https://doi.org/10.1007/s11357-010-9132-1.

114. Myllykangas L, Polvikoski T, Sulkava R, Verkkoniemi A, Tienari P, Niinisto L, et al. Cardiovascular risk factors and Alzheimer’s disease: a genetic association study in a population aged 85 or over. Neurosci Lett. 2000;292:195–8.

115. Morris J, Heyman A, Mohs R, Hughes J, van Belle G, Fillenbaum G, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD) Part I Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989;39:1159. https://doi.org/10.1212/WNL.39.9.1159.

116. Abikoff H, Alvir J, Hong G, Sukoff R, Orazio J, Solomon S, et al. Logical memory subtest of the Wechsler memory scale: age and education norms and alternate-form reliability of two scoring systems. J Clin Exp Neuropsychol. 1987;9:435–48. https://doi.org/10.1080/01688638708405063.

117. Rey A. L’examen clinique en psychologie (the clinical examination in psychology). Paris: Presses Universitaires de France; 1964.

118. Meyers JE, Bayless JD, Meyers KR. Rey complex figure: memory error patterns and functional abilities. Appl Neuropsychol. 1996;3:89–92. https://doi.org/10.1207/s15324826an0302.

119. Cronholm B, Viding G. Digit span as a test of immediate memory. Nord Med. 1956;56:1612–4.

120. Wechsler D. The psychological corporation. TX: San Antonio; 1997.

121. Tombaugh T. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol. 1999;14:167–77.

122. Royall DR, Cordes JA, Polk M. CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry. 1998;64:588–94.

123. McKenna PAT, Warrington EK. Testing for nominal dysphasia. J Neurol Neurosurg Psychiatry. 1980;43:781–8.

124. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271–6.

125. Wechsler D. Wechsler adult intelligence scale - revised manual; 1981.

126. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Robbitt P. Cambridge neuropsychological test automated battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia. 1994;5:266–81.

127. Nelson HE, O’Connell A. Dementia: the estimation of premorbid intelligence levels using the new adult Reading test. Cortex. 1978;14:234–44.

128. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 2002;73:126–33.

129. Moshio E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke’s cognitive examination revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21:1078–85.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Legdeur, N; Badissi, M; Carter, SF; de Crom, S; van de Kreeke, A; Vreeswijk, R; Trappenburg, MC; Oudega, ML; Koek, HL; van Campen, JP; Keijzers, CJPW; Amadi, C; Hinz, R; Gordon, MF; Novak, G; Podhorna, J; Serne, E; Verbraak, F; Yaqub, M; Hillebrand, A; Griffa, A; Pendleton, N; Kramer, SE; Teunissen, CE; Lammertsma, A; Barkhof, F; van Berckel, BNM; Scheltens, P; Muller, M; Maier, AB; Herholz, K; Visser, PJ

Title:
Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+study

Date:
2018-11-26

Citation:
Legdeur, N., Badissi, M., Carter, S. F., de Crom, S., van de Kreeke, A., Vreeswijk, R., Trappenburg, M. C., Oudega, M. L., Koek, H. L., van Campen, J. P., Keijzers, C. J. P. W., Amadi, C., Hinz, R., Gordon, M. F., Novak, G., Podhorna, J., Serne, E., Verbraak, F., Yaqub, M. ,... Visser, P. J. (2018). Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+study. BMC GERIATRICS, 18 (1), https://doi.org/10.1186/s12877-018-0984-z.

Persistent Link:
http://hdl.handle.net/11343/249956

File Description:
published version

License:
CC BY